Načítá se...
Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
PURPOSE: The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, including 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRA...
Uloženo v:
| Vydáno v: | Yonsei Med J |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Yonsei University College of Medicine
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7515783/ https://ncbi.nlm.nih.gov/pubmed/32975057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.10.837 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|